Literature DB >> 7441848

A plea for conservation of kidney in renal adenocarcinoma associated with von Hippel-Lindau disease.

J C Pearson, J Weiss, E A Tanagho.   

Abstract

We report 3 cases of bilateral renal cell carcinoma associated with von Hippel-Lindau disease. Treatment consisted of local excision or simply shelling out of the lesion from the surrounding tissue. The 3 patients are free of disease (followup 6 to 36 months). Although multifocal the lesions are removed easily; thus, normal renal function is preserved and patients are spared the morbidity and mortality associated with hemodialysis or transplantation.

Entities:  

Mesh:

Year:  1980        PMID: 7441848     DOI: 10.1016/s0022-5347(17)55726-2

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

Review 1.  Long-term management of bilateral, multifocal, recurrent renal carcinoma.

Authors:  Gennady Bratslavsky; W Marston Linehan
Journal:  Nat Rev Urol       Date:  2010-05       Impact factor: 14.432

2.  Renal carcinoma in Lindau's disease.

Authors:  V Nagendran; A H Dimond
Journal:  Postgrad Med J       Date:  1984-09       Impact factor: 2.401

3.  Nephron-sparing surgery for renal cell carcinoma.

Authors:  K H Tsui; A van Ophoven; O Shvarts; A Belldegrun
Journal:  Rev Urol       Date:  1999

4.  Enucleation procedures in patients with multiple hereditary renal tumors.

Authors:  M M Walther; N Thompson; W Linehan
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

5.  Segregation and linkage analyses of von Hippel Lindau disease among 220 descendants from one kindred.

Authors:  R C Go; J M Lamiell; Y E Hsia; J W Yuen; Y Paik
Journal:  Am J Hum Genet       Date:  1984-01       Impact factor: 11.025

Review 6.  A 25 year perspective on the evolution and advances in an understanding of the biology, evaluation and treatment of kidney cancer.

Authors:  Daniel M Geynisman; Jodi K Maranchie; Mark W Ball; Gennady Bratslavsky; Eric A Singer
Journal:  Urol Oncol       Date:  2021-06-04       Impact factor: 2.954

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.